1,676 reports of this reaction
1.3% of all ONABOTULINUMTOXINA reports
#16 most reported adverse reaction
DYSPHAGIA is the #16 most commonly reported adverse reaction for ONABOTULINUMTOXINA, manufactured by Allergan, Inc.. There are 1,676 FDA adverse event reports linking ONABOTULINUMTOXINA to DYSPHAGIA. This represents approximately 1.3% of all 126,795 adverse event reports for this drug.
ONABOTULINUMTOXINA has an overall safety score of 78 out of 100. Patients taking ONABOTULINUMTOXINA who experience dysphagia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPHAGIA is a less commonly reported adverse event for ONABOTULINUMTOXINA, but still significant enough to appear in the safety profile.
In addition to dysphagia, the following adverse reactions have been reported for ONABOTULINUMTOXINA:
The following drugs have also been linked to dysphagia in FDA adverse event reports:
DYSPHAGIA has been reported as an adverse event in 1,676 FDA reports for ONABOTULINUMTOXINA. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPHAGIA accounts for approximately 1.3% of all adverse event reports for ONABOTULINUMTOXINA, making it a notable side effect.
If you experience dysphagia while taking ONABOTULINUMTOXINA, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.